Maintain Scientific Leadership: Leverage OSE Immunotherapeutics’ differentiated research engine to fuel innovation for rare ...
Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...
Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging ...
In the charred remains of what was once his home in Udhayasuriyan Nagar, Vyasarpadi, a student sits cross-legged on blackened ...
Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...
Viva Gold Corp. is pleased announce that the Company's President and CEO Jim Hesketh will be participating in a live webcast presentation at the John Tumazos Very Independent Research, LLC virtual ...
From December 1-4, our Women in Business Club went on a field trip to Boston. Thanks to Kelly Kimball, MBA Adjunct Professor, ...
The SOM held its annual Sustainable Development Goals Competition. The Women in Business Club visited Harvard, Dunkin Donuts, ...
(NYSE: BOX), the leading Intelligent Content Management (ICM) platform, today announced that the Heart Research Institute (HRI), a renowned medical research institute, selected Box to centralise and ...
Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback